Search Results - (Author, Cooperation:M. S. Hirsch)
-
1Latest Papers from Table of Contents or Articles in PressT. Ni Chonghaile ; K. A. Sarosiek ; T. T. Vo ; J. A. Ryan ; A. Tammareddi ; G. Moore Vdel ; J. Deng ; K. C. Anderson ; P. Richardson ; Y. T. Tai ; C. S. Mitsiades ; U. A. Matulonis ; R. Drapkin ; R. Stone ; D. J. Deangelo ; D. J. McConkey ; S. E. Sallan ; L. Silverman ; M. S. Hirsch ; D. R. Carrasco ; A. Letai
American Association for the Advancement of Science (AAAS)
Published 2011Staff ViewPublication Date: 2011-10-29Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: Adult ; Aged ; Animals ; Antineoplastic Agents/*therapeutic use ; *Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Child ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Humans ; Leukemia, Myeloid, Acute/drug therapy/physiopathology ; Male ; Membrane Potential, Mitochondrial ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Mitochondria/*physiology ; Multiple Myeloma/drug therapy/physiopathology ; Neoplasms/*drug therapy/*physiopathology ; Ovarian Neoplasms/drug therapy/physiopathology ; Peptide Fragments/metabolism ; Permeability ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/physiopathology ; Proto-Oncogene Proteins c-bcl-2/chemistry/metabolism ; Remission Induction ; Signal TransductionPublished by: -
2Latest Papers from Table of Contents or Articles in PressTucker, D. W., Getchell, C. R., McCarthy, E. T., Ohman, A. W., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A., Medina, J. E., Lee, J. J., Mac; Donald, L. A., Malik, A., Hasselblatt, K. T., Li, W., Zhang, H., Kaplan, S. J., Murphy, G. F., Hirsch, M. S., Liu, J. F., Matulonis, U. A., Terry, K. L., Lian, C. G., Dinulescu, D. M.
The American Association for Cancer Research (AACR)
Published 2018Staff ViewPublication Date: 2018-03-16Publisher: The American Association for Cancer Research (AACR)Print ISSN: 1078-0432Electronic ISSN: 1557-3265Topics: MedicinePublished by: -
3Articles: DFG German National LicensesGAUGAS, J. M. ; CHESTERMAN, F. C. ; HIRSCH, M. S. ; REES, R. J. W. ; HARVEY, JENNIFER J. ; GILCHRIST, C.
[s.l.] : Nature Publishing Group
Published 1969Staff ViewISSN: 1476-4687Source: Nature Archives 1869 - 2009Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsNotes: [Auszug] During an attempt to transmit human leprosy (Mycobacterium leprae) to mice, polyoma-type tumours arose in all mice thymectomized as adults and treated with anti-lymphocytic globulin (ALS ...Type of Medium: Electronic ResourceURL: -
4Articles: DFG German National LicensesStaff View
ISSN: 1476-4687Source: Nature Archives 1869 - 2009Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsNotes: [Auszug] Oldstone and Dixon8'9 have recently reported that mice neonatally infected with LCM virus are not completely tolerant to this agent, but make antibodies detectable only in renal glomeruli where they are presumably deposited in the form of antigen-antibody complexes. Our observations suggest that ...Type of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesStaff View
ISSN: 1476-4687Source: Nature Archives 1869 - 2009Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsNotes: [Auszug] ICR Swiss mice between 28 and 35 days old were used. The virus preparation was supplied by Dr Frank J. Rauscher, National Cancer Institute, Bethesda, Maryland; it was prepared from BALB/c mouse spleens according to established techniques10. RAMT serum was prepared as described by Levey and Medawar3 ...Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesStaff View
ISSN: 1476-4687Source: Nature Archives 1869 - 2009Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsNotes: [Auszug] Fig. 1. Comparison of times of death in groups treated with normal rabbit serum (NRS) or rabbit anti-mouse thymocyte (RAMT) serum,at virus dilutions from 1Q-1 to 1Q-5. Adult ICE mice of both sexes were used in all experiments. RAMT serum was prepared as described by Levey and Medawar5, and assayed ...Type of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesConway, B. ; Baskar, P. ; Bechtel, L. J. ; Kaplan, Joan C. ; Hirsch, M. S. ; Schooley, R. T. ; Pincus, Stephanie H.
Springer
Published 1992Staff ViewISSN: 1432-8798Source: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Transient expression of HIV-1 p24 antigen was observed in eosinophils acutely infected with the HTLV-IIIB strain of HIV-1. PCR analysis of eosinophils isolated from 18 seropositive individuals showed HIV-1 sequences to be present in 2 subjects. These data suggest that eosinophils may act as host cells for HIV-1.Type of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesMargalith, M. ; D'Aquila, R. T. ; Manion, D. J. ; Basgoz, N. ; Bechtel, L. J. ; Smith, B. R. ; Kaplan, J. C. ; Hirsch, M. S.
Springer
Published 1995Staff ViewISSN: 1432-8798Source: Springer Online Journal Archives 1860-2000Topics: MedicineNotes: Summary Interactions between HIV-1 and CMV may be important in the pathogenesis of AIDS. We have studied whether active CMV infection alters the cell tropism of HIV-1 in dually-infected individuals. Urines from HIV-seropositive individuals excreting CMV were compared to urines from CMV non-excretors. Sixty-six urines from HIV-seropositive individuals were tested. Infectious HIV-1 was not detected in any of the concentrated urines tested. The urines were filtered, concentrated, DNase-treated and cultured on HIV-1 non-permissive human forestin fibroblasts. HIV-1 DNA was detected by PCR withpol gene primers in 5 of 39 MRHF cell cultures inoculated with CMV culture positive urine (p=0.037). HIV-1 DNA was not detected by PCR in uninfected fibroblasts, in fibroblasts inoculated with CMV uninfected urine from 27 HIV-seropositive patients or in fibroblasts cultured with 9 CMV culture positive urines from 16 HIV-seronegative renal transplant recipients. Supernatant fluid from an HIV-1 PCR-positive culture was passaged onto another fibroblast monolayer, and these cells were negative for HIV-1 DNA. Direct inoculation of fibroblasts with HIV-1 did not yield evidence of infection by PCR. CMV infection may facilitate HIV-1 DNA entry into ordinarily non-permissive cells.Type of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesWhitley, R. J. ; Alford, C. A. ; Hirsch, M. S. ; Schooley, R. T. ; Luby, J. P. ; Aoki, F. Y. ; Hanley, D. ; Nahmias, A. J. ; Soong, S. J.
Springer
Published 1987Staff ViewISSN: 1439-0973Source: Springer Online Journal Archives 1860-2000Topics: MedicineDescription / Table of Contents: Zusammenfassung Bei 208 Patienten wurde wegen Verdachts auf Herpes simplex-Enzephalitis eine Gehirnbiopsie durchgeführt. Nach Randomisierung wurde entweder mit Vidarabin in einer Dosierung von 15 mg/kg pro Tag oder mit 30 mg/kg/Tag Aciclovir für zehn Tage behandelt. Bei 69 der biopsierten Patienten (33%) wurde die Diagnose bestätigt, von ihnen erhielten 37 Vidarabin und 32 Aciclovir. Die demographischen Charakteristika der beiden Gruppen waren mit Ausnahme des Alters vergleichbar. 18 Monate nach der Therapie waren 72% der mit Aciclovir behandelten und 46% der mit Vidarabin behandelten Patienten am Leben (p=0,008). Nach Ausgleich der Altersunterschiede in den beiden Patientengruppen mittels Multivarianten-Regressionsanalyse blieb Aciclovir gegenüber Vidarabin immer noch therapeutisch überlegen (p=0,041). Je nach Grad der Bewußtseinsstörung zu Beginn der Therapie war die Sterblichkeit unterschiedlich hoch. Die Letalität nahm von Lethargie zu Semikoma und Koma von 42% auf 46% und 67% bei mit Vidarabin und von 0% auf 25% und 25% bei mit Aciclovir behandelten Patienten zu. Nachuntersuchungen bezüglich Restschäden sechs Monate nach Therapie ergaben bei fünf mit Vidarabin (14%) und 12 mit Aciclovir (38%) behandelten Patienten eine vollkommene Wiederherstellung und bei acht (22%) bzw. drei (9%) eine mäßiggradige zerebrale Funktionseinschränkung. Die Unterschiede der Therapieergebnisse erwiesen sich bei Anwendung eines angepaßten Punktesystems als signifikant mit p=0,02 (Zwei-Proben-Test nach Wilcoxon). Bei einer Punktezahl von mehr als 10 im Glasgow Koma-Schema war das Ergebnis nach Aciclovir-Behandlung am günstigsten. Bei bewußtseinsgestörten Patienten mit erhaltenen Reflexen und Augenreaktionen auf Schmerzreiz traten keine Todesfälle auf, 50% der Patienten wurden völlig wiederhergestellt. Aufgrund dieser Daten ist Aciclovir als Therapie der Wahl bei bioptisch gesicherter Herpes simplex-Enzephalitis anzusehen.Notes: Summary A total of 208 patients underwent brain biopsy for presumptive herpes simplex encephalitis and were randomized to receive either vidarabine, vira-A, at 15 mg/kg/day, or acyclovir, at 30 mg/kg/day for ten days. 69 patients (33%) had biopsy-proven disease; 37 received vira-A and 32 acyclovir. With the exception of age, patient populations were balanced for demographic characteristics. Overall survival for acyclovir recipients was 72% compared with 46% for vira-A-treated patients 18 months after therapy (p=0.008). After adjustment for differences of age between treatment populations by multivariant regression analyses, acyclovir treatment remained superior to vidarabine therapy (p=0.041). Mortality varied according to the level of consciousness at the onset of therapy. For lethargic, semicomatose and comatose patients, mortality was 42%, 46%, and 67%, respectively, for the vira-A-treated patients and 0%, 25% and 25%, respectively, for acyclovir-treated patients. Six months post-therapy morbidity assessments revealed five (14%) vira-A versus 12 (38%) acyclovir recipients who had returned to normal function, while eight (22%) and three (9%), respectively, had moderate debility. Outcome differences were significant (p=0.02; Wilcoxon, 2-sample test) using an adapted scoring system. Age and Glasgow coma scale 〉 10 predicted the best outcome following acyclovir treatment. Disoriented patients who flex and respond by eye to pain had no mortality and 50% returned to normal. These data indicate that acyclovir is the treatment of choice for biopsy-proven herpes simplex encephalitis.Type of Medium: Electronic ResourceURL: